S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon

Zentalis Pharmaceuticals (ZNTL) Competitors

$12.96
+0.42 (+3.35%)
(As of 04/19/2024 ET)

ZNTL vs. MGNX, CNTA, SAVA, LQDA, BLTE, MNKD, ARQT, OCUL, ETNB, and IMNM

Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include MacroGenics (MGNX), Centessa Pharmaceuticals (CNTA), Cassava Sciences (SAVA), Liquidia (LQDA), Belite Bio (BLTE), MannKind (MNKD), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), 89bio (ETNB), and Immunome (IMNM). These companies are all part of the "pharmaceutical preparations" industry.

Zentalis Pharmaceuticals vs.

MacroGenics (NASDAQ:MGNX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability.

MacroGenics has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

96.9% of MacroGenics shares are owned by institutional investors. 10.0% of MacroGenics shares are owned by insiders. Comparatively, 6.1% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MacroGenics has higher revenue and earnings than Zentalis Pharmaceuticals. MacroGenics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$58.75M16.62-$9.06M-$0.16-97.56
Zentalis PharmaceuticalsN/AN/A-$292.19M-$4.54-2.85

MacroGenics received 367 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. However, 64.10% of users gave Zentalis Pharmaceuticals an outperform vote while only 63.28% of users gave MacroGenics an outperform vote.

CompanyUnderperformOutperform
MacroGenicsOutperform Votes
417
63.28%
Underperform Votes
242
36.72%
Zentalis PharmaceuticalsOutperform Votes
50
64.10%
Underperform Votes
28
35.90%

MacroGenics presently has a consensus target price of $17.00, suggesting a potential upside of 8.90%. Zentalis Pharmaceuticals has a consensus target price of $38.57, suggesting a potential upside of 197.62%. Given MacroGenics' higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than MacroGenics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88
Zentalis Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

In the previous week, MacroGenics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for Zentalis Pharmaceuticals. MacroGenics' average media sentiment score of 1.02 beat Zentalis Pharmaceuticals' score of 0.25 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MacroGenics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zentalis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Zentalis Pharmaceuticals' net margin of -15.42%. MacroGenics' return on equity of -63.93% beat Zentalis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-15.42% -88.49% -43.12%
Zentalis Pharmaceuticals N/A -63.93%-51.99%

Summary

MacroGenics beats Zentalis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZNTL vs. The Competition

MetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$919.64M$7.01B$4.99B$7.31B
Dividend YieldN/A3.13%2.94%3.99%
P/E Ratio-2.8517.78242.4520.06
Price / SalesN/A305.042,451.4593.00
Price / CashN/A28.8947.1734.42
Price / Book2.105.504.564.15
Net Income-$292.19M$150.33M$104.50M$214.00M
7 Day Performance-3.36%-6.76%-4.52%-3.51%
1 Month Performance-5.47%-9.64%-6.80%-6.05%
1 Year Performance-38.29%-7.24%6.57%3.98%

Zentalis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGNX
MacroGenics
2.8879 of 5 stars
$18.10
-1.4%
$17.00
-6.1%
+126.9%$1.13B$57.19M-113.13339Gap Up
CNTA
Centessa Pharmaceuticals
0.6606 of 5 stars
$11.31
+5.1%
$10.00
-11.5%
+113.1%$1.10B$6.85M-7.2075
SAVA
Cassava Sciences
3.4975 of 5 stars
$25.40
+7.8%
$124.00
+388.2%
+17.7%$1.10BN/A-10.9529High Trading Volume
LQDA
Liquidia
2.0674 of 5 stars
$14.96
-1.1%
$21.00
+40.4%
+96.0%$1.14B$17.49M-12.47145Insider Selling
News Coverage
BLTE
Belite Bio
2.24 of 5 stars
$40.03
+0.1%
$44.83
+12.0%
+12.0%$1.17BN/A-32.2820
MNKD
MannKind
2.119 of 5 stars
$4.44
-2.4%
$8.00
+80.2%
+3.7%$1.20B$198.96M-88.80411Positive News
ARQT
Arcutis Biotherapeutics
1.355 of 5 stars
$12.49
-0.3%
$26.56
+112.6%
-32.3%$1.21B$59.61M-3.19296Positive News
OCUL
Ocular Therapeutix
3.5591 of 5 stars
$8.17
+2.3%
$16.80
+105.6%
-8.7%$1.21B$58.44M-6.54267Analyst Report
News Coverage
ETNB
89bio
1.196 of 5 stars
$10.90
+1.0%
$28.83
+164.5%
-44.7%$1.02BN/A-5.4270Positive News
IMNM
Immunome
1.6278 of 5 stars
$20.48
+1.7%
$31.50
+53.8%
+191.5%$1.22B$14.02M-3.8037

Related Companies and Tools

This page (NASDAQ:ZNTL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners